View in EDS

Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).

Saved in:
Bibliographic Details
Title: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Authors: Blauvelt A; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com., Ladizinski B; AbbVie Inc, North Chicago, Illinois., Prajapati VH; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada., Laquer V; First OC Dermatology Research, Fountain Valley, California., Fischer A; Southside Dermatology, Tulsa, Oklahoma; Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma., Eisman S; Sinclair Dermatology, East Melbourne, Victoria, Australia., Hu X; AbbVie Inc, North Chicago, Illinois., Wu T; AbbVie Inc, North Chicago, Illinois., Calimlim BM; AbbVie Inc, North Chicago, Illinois., Kaplan B; AbbVie Inc, North Chicago, Illinois., Liu Y; AbbVie Inc, North Chicago, Illinois., Teixeira HD; AbbVie Inc, North Chicago, Illinois., Liu J; AbbVie Inc, North Chicago, Illinois., Eyerich K; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Dermatology and Venerology, School of Medicine, University of Freiburg, Freiburg, Germany.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Sep; Vol. 89 (3), pp. 478-485. Date of Electronic Publication: 2023 May 23.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37230366
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Blauvelt+A%22">Blauvelt A</searchLink>; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com.<br /><searchLink fieldCode="AU" term="%22Ladizinski+B%22">Ladizinski B</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Prajapati+VH%22">Prajapati VH</searchLink>; Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada.<br /><searchLink fieldCode="AU" term="%22Laquer+V%22">Laquer V</searchLink>; First OC Dermatology Research, Fountain Valley, California.<br /><searchLink fieldCode="AU" term="%22Fischer+A%22">Fischer A</searchLink>; Southside Dermatology, Tulsa, Oklahoma; Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma.<br /><searchLink fieldCode="AU" term="%22Eisman+S%22">Eisman S</searchLink>; Sinclair Dermatology, East Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Hu+X%22">Hu X</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Wu+T%22">Wu T</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Calimlim+BM%22">Calimlim BM</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Kaplan+B%22">Kaplan B</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Teixeira+HD%22">Teixeira HD</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Liu+J%22">Liu J</searchLink>; AbbVie Inc, North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Eyerich+K%22">Eyerich K</searchLink>; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Dermatology and Venerology, School of Medicine, University of Freiburg, Freiburg, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227907132%22">Journal of the American Academy of Dermatology</searchLink> [J Am Acad Dermatol] 2023 Sep; Vol. 89 (3), pp. 478-485. <i>Date of Electronic Publication: </i>2023 May 23.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mosby%22">Mosby </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7907132 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-6787 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201909622%22">01909622 </searchLink><i>NLM ISO Abbreviation: </i>J Am Acad Dermatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37230366
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jaad.2023.05.033
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 478
    Titles:
      – TitleFull: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Blauvelt A
      – PersonEntity:
          Name:
            NameFull: Ladizinski B
      – PersonEntity:
          Name:
            NameFull: Prajapati VH
      – PersonEntity:
          Name:
            NameFull: Laquer V
      – PersonEntity:
          Name:
            NameFull: Fischer A
      – PersonEntity:
          Name:
            NameFull: Eisman S
      – PersonEntity:
          Name:
            NameFull: Hu X
      – PersonEntity:
          Name:
            NameFull: Wu T
      – PersonEntity:
          Name:
            NameFull: Calimlim BM
      – PersonEntity:
          Name:
            NameFull: Kaplan B
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Teixeira HD
      – PersonEntity:
          Name:
            NameFull: Liu J
      – PersonEntity:
          Name:
            NameFull: Eyerich K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2023 Sep
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1097-6787
          Numbering:
            – Type: volume
              Value: 89
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Journal of the American Academy of Dermatology
              Type: main
ResultId 1